666 931

Cited 55 times in

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization

DC Field Value Language
dc.contributor.author이도연-
dc.contributor.author이용강-
dc.contributor.author전재윤-
dc.contributor.author한광협-
dc.contributor.author김도영-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이광훈-
dc.date.accessioned2014-12-18T08:30:51Z-
dc.date.available2014-12-18T08:30:51Z-
dc.date.issued2013-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/86450-
dc.description.abstractBACKGROUND/AIMS: Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) have been used as diagnostic tools for hepatocellular carcinoma (HCC). However, prediction of outcome using AFP and DCP has not been elucidated. We investigated the clinical role of AFP and DCP as predictors of treatment outcome in patients with HCC undergoing trans-arterial chemoembolization (TACE). METHODS: Between January 2003 and December 2005, we enrolled 115 treatment-naïve patients who received TACE as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 50% from the baseline level 1 month after TACE. Patients with AFP < 20 ng/mL or DCP < 20 mAU/mL were excluded. RESULTS: The median age was 59 years and the male gender predominated (n = 81, 70.4%). AFP and DCP response was identified in 91 (79.1%) and 77 (66.9%) patients after TACE. Although progression-free survival (PFS) did not differ according to AFP response (P = 0.150), AFP responders showed significantly better overall survival (OS) than non-responders (34.9 vs. 13.2 months; P = 0.002). In contrast, DCP response did not influence either PFS or OS (all P > 0.05). Multivariate analyses showed that gamma-glutamyltranspeptidase and baseline AFP were predictors of PFS (all P < 0.05) and that male gender, the presence of liver cirrhosis, baseline DCP, number of measurable tumors and AFP response were independent predictors of OS (all P < 0.05). CONCLUSIONS: AFP response and higher baseline DCP level are significant predictors of OS in treatment-naïve patients with HCC receiving TACE who showed pretreatment elevation of both AFP and DCP.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfBMC CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titlePrognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiology (영상의학)-
dc.contributor.googleauthorYong Kang Lee-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang Hun Lee-
dc.contributor.googleauthorDo Yun Lee-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorChae Yoon Chon-
dc.contributor.googleauthorJun Yong Park-
dc.identifier.doi10.1186/1471-2407-13-5-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02718-
dc.contributor.localIdA02973-
dc.contributor.localIdA04268-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA02674-
dc.contributor.localIdA03544-
dc.contributor.localIdA00385-
dc.relation.journalcodeJ00351-
dc.identifier.eissn1471-2407-
dc.identifier.pmidAlpha-fetoprotein ; Des gamma carboxy prothrombin ; Transarterial chemoembolization ; Tumor marker response ; Hepatocellular carcinoma ; Prognosis ; Survival-
dc.subject.keywordAlpha-fetoprotein-
dc.subject.keywordDes gamma carboxy prothrombin-
dc.subject.keywordTransarterial chemoembolization-
dc.subject.keywordTumor marker response-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordPrognosis-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameLee, Do Yun-
dc.contributor.alternativeNameLee, Yong Kang-
dc.contributor.alternativeNameChon, Chae Yoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameLee, Kwang Hoon-
dc.contributor.affiliatedAuthorLee, Do Yun-
dc.contributor.affiliatedAuthorLee, Yong Kang-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Seung Up-
dc.contributor.affiliatedAuthorPark, Jun Yong-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorLee, Kwang Hoon-
dc.contributor.affiliatedAuthorChon, Chae Yoon-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.rights.accessRightsfree-
dc.citation.volume13-
dc.citation.startPage5-
dc.identifier.bibliographicCitationBMC CANCER, Vol.13 : 5, 2013-
dc.identifier.rimsid28990-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.